Deck

SKC Co., Ltd. · 011790 · KRX

SKC is a Korean SK Group affiliate that owns four unrelated specialty-materials businesses — copper foil for EV batteries, a 45% stake in separately-listed AI test-socket maker ISC, commodity propylene-glycol chemicals, and a pre-revenue glass-substrate venture in Georgia.

$109
Price (May 8, 2026)
$4.1B
Market cap
$1.27B
Revenue (FY2025)
1973
Founded
Traded around $26 a decade ago; peaked at an all-time high of $174 in November 2021 on the EV-battery boom; drew down 60% into a March 2026 low of $58 before rallying +75% in six weeks to $109.
2 · Half the cap is one listed subsidiary

SKC owns 45% of a separately-listed AI test-socket maker — that stake alone is 40% of the market cap.

  • The mark. SKC's 45.03% stake in KOSDAQ-listed ISC marks at $1.65B against SKC's $4.1B market cap. ISC printed $41M operating profit on $152M revenue at 27% margin in FY25, then +236% YoY operating profit at 35% margin in 1Q26 on AI/HBM tester demand.
  • The multiple. ISC trades at 95× trailing P/E and ~22× the implied EV/Sales of LEENO Industrial, its closest pure-play peer. The premium pays for AI/HBM design-in lock SKC management does not control — if AI capex disappoints or HBM share rotates to Micron, the largest single mark in the SOTP would compress with nothing else changing.
  • The hidden bet. The 9-analyst consensus target of $72 only closes mathematically if ISC compresses 25–30% from its KOSDAQ mark — but no covering analyst has explicitly underwritten that view. A short on SKC is implicitly a short on the AI cycle through ISC.
The biggest single risk in this stock is not copper foil — it is ISC's own multiple.
3 · The 1Q26 inflection — real or artifact?

First positive consolidated EBITDA in eleven quarters. The bear case is whether 5 August holds it.

+$7M
1Q26 EBITDA first positive since 2Q23
+$6.5M
Chemicals OP first positive since 3Q22
+403%
Copper-foil NA volume YoY in 1Q26
+236%
ISC operating profit YoY at 35% margin

Three engines moved together for the first time in two years — chemicals swung positive on a Mid-East PG-spread spike, the Malaysia copper-foil plant turned standalone EBITDA-positive on volume pull-through, and ISC posted record AI-socket margins. The bear's wedge is that 4Q25 booked an unquantified $218M write-down of "manufacturing-equipment optimization" right before the rights raise, flattering the QoQ comparison. The 5 August 2Q26 print is the first clean comparison — a second consecutive positive print with chemicals OP retained validates the inflection; reversion to negative validates the artifact reading.

4 · The capital reset

$680M rights offering lists 8 June; new CEO has one earnings cycle of credibility.

  • Mechanical 22% dilution lands 8 June. SK Inc. (40.64% controller) committed to 120% of pro-rata; ESOP demand survey 132% oversubscribed. $401M routes to Absolics + AMAT collaboration; $279M retires debt — D/E drops from 233% to 142% post-deal.
  • The CEO conflict cleared. Kim Jong-woo replaced Park Won-cheol on 26 March 2026, ending the prior CEO's dual role at SKC parent and Absolics — a structural conflict now resolved. New mandate: "stability, recovery, growth." CFO Park Dong-ju was hired from SK Inc. portfolio planning in late 2025.
  • Four years of credibility damage. Six of ten valuation-relevant promises since 2022 were missed or quietly abandoned — the 250kt copper-foil capacity target, the silicon-anode roadmap, and the $1.7B net-debt target. The asset-disposal program ($616M in 2025 across CMP Pad, FCCL, blank mask) did deliver. The new CEO inherits both records.
A clean clearing of the 8 June listing turns dilution from overhang to recap; a discount-then-gap-down listing is the bear's confirmation.
5 · The tape vs. the analysts

+75% in six weeks at decade-high vol, into a 22% mechanical dilution and an UNDERPERFORM consensus.

  • The blow-off. 30-day realized volatility hit 117% on 7 May — the highest in ten years, 33–48 points above any prior peak (2021-Q4 79%; 2024-Q2 80%; 2025-Q1 88%). Price sits 49.5% above the 200-day SMA, RSI ~70. May 7 traded 2.76M shares — 6.6× the 50-day average.
  • The institutions disagree. 9 sell-side analysts cover with mean UNDERPERFORM and 12-month target $72 (-34% from spot). Nomura at "Reduce" / $61. JPMorgan at Sell / $49 (cut from $57 on 2 March). Goldman Sachs at Sell / $55 (28 April). Macquarie maintained Hold / $88 on 29 April — no covering analyst has upgraded into the rally.
  • The arithmetic trap. $72 × 37.9M shares = $2.73B market cap. Subtract the $1.65B ISC mark and "everything else" residual = $1.08B — which only closes if consensus is also implicitly short the AI cycle through ISC. Either the targets quietly assume ISC compresses, or they are mathematically inconsistent with the listed mark.
Tape, consensus, and dilution math each imply a different model of the world. The next 90 days will test which one holds.
6 · Bull & Bear

Lean watchlist — every load-bearing variable resolves on one print on or around 5 August 2026.

  • For. ISC stake covers ~40% of cap and compounds at AI-cycle rates without requiring SKC parent execution; at LEENO multiples, the parent share alone exceeds $2.1B.
  • For. Three-engine 1Q26 print — chemicals reverting, copper-foil NA pull-through, ISC growth — moved together on segment-level evidence the 4Q25 impairment wedge does not retroactively flatter.
  • Against. $410M FY25 below-the-line losses widened every year ($142M FY23 → $262M FY24 → $410M FY25), undisaggregated in English filings, ahead of a rights raise — textbook big-bath signature.
  • Against. 117% realized vol, +49.5% above the 200d SMA, into uniformly negative sell-side coverage is what crisis-driven blow-offs look like, not orderly trends.
My view — wait for confirmation, not anticipation. A 2Q26 EBITDA print > +$14M with chemicals OP still positive would shift this to lean long; reversion to negative paired with any 15%+ ISC compression would shift it to avoid.

Watchlist to re-rate: Daily KOSDAQ:095340 mark on ISC (40% of SKC cap, prints continuously); 8 June listing-day tape and post-listing absorption over four weeks; 5 August 2Q26 EBITDA print and chemicals OP retention.